Clinical Trial Update: RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating RO4929097 with erlotinib hydrochloride in stage IV or recurrent non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED